Research progress of anticoagulation combined with antiplatelet treatment strategy in acute coronary syndrome
10.3760/cma.j.jssn.1673-4904.2016.06.026
- VernacularTitle:急性冠状动脉综合征抗凝抗血小板联合治疗策略研究进展
- Author:
Yanguo XIN
;
Wen TIAN
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Anticoagulants;
Fibrinolytic agents
- From:
Chinese Journal of Postgraduates of Medicine
2016;39(6):567-570
- CountryChina
- Language:Chinese
-
Abstract:
Dual antiplatelet therapy is the standard treatment for patients with acute coronary syndrome (ACS) and coronary heart disease interventional treatment. Clopidogrel, a traditional antiplatelet agent, has some disadvantages, such as slow onset time, individual differences and dissatisfy the antithrombosis requirement in ischemia of high-risk patients. In addition, for ACS patients with indications of anticoagulation, antiplatelet therapy cannot prevent venous thromboembolic events. However, dual antiplatelet combined with anticoagulant therapy may decrease the risk of ischemic events at the price of increasing bleeding. With the development of new antithrombotic agents, the antithrombotic strategy for ACS has made some progress, such as antiplatelet strategy for ACS, antithrombotic strategy for ACS with indication of anticoagulation and new antithrombotic drugs. With the development of clinical antithrombotic drug research, the patients with ACS will benefit from the optimized strategy of combined with antithrombotic therapy.
